Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA.
Am J Hematol. 2010 Jan;85(1):6-13. doi: 10.1002/ajh.21550.
Sickle cell disease (SCD) is a pleiotropic genetic disorder of hemoglobin that has profound multiorgan effects. The low prevalence of SCD ( approximately 100,000/US) has limited progress in clinical, basic, and translational research. Lack of a large, readily accessible population for clinical studies has contributed to the absence of standard definitions and diagnostic criteria for the numerous complications of SCD and inadequate understanding of SCD pathophysiology. In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish consensus definitions of the most frequently occurring complications. A group of clinicians and scientists with extensive expertise in research and treatment of SCD gathered to identify and categorize the most common complications. From this group, a formal writing team was formed that further reviewed the literature, sought specialist input, and produced definitions in a standard format. This article provides an overview of the process and describes 12 body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are better understood, and new diagnostic options are developed.
镰状细胞病(SCD)是一种血红蛋白的多效性遗传疾病,对多个器官有深远的影响。由于 SCD 的发病率较低(约 10 万/美国),因此在临床、基础和转化研究方面进展有限。缺乏一个庞大且易于获得的人群进行临床研究,导致 SCD 的许多并发症缺乏标准定义和诊断标准,也无法充分了解 SCD 的病理生理学。2005 年,综合镰状细胞中心启动了一个项目,旨在建立最常见并发症的共识定义。一组在 SCD 的研究和治疗方面具有丰富专业知识的临床医生和科学家聚集在一起,以确定和分类最常见的并发症。从这个小组中,成立了一个正式的写作团队,进一步审查了文献,征求了专家的意见,并以标准格式制定了定义。本文概述了这一过程,并描述了 12 个体系统类别以及这些类别中的最常见或最严重的并发症。详细的附录提供了每个系统中确定的所有并发症的标准化定义。本报告建议在 SCD 并发症的研究中使用这些定义,以便未来的研究可以具有可比性,并且可以衡量治疗效果。使用这些定义将支持更准确的基因型-表型研究,从而更好地了解 SCD 的病理生理学。然而,这应该被视为一个动态而不是最终的文件;应定期重新评估和修订表型描述,以提供最新的标准定义,因为随着病因的更好理解和新的诊断选择的发展,表型描述应进行定期评估和修订。